These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35651850)

  • 21. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
    Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
    Svensson MC; Borg D; Zhang C; Hedner C; Nodin B; Uhlén M; Mardinoglu A; Leandersson K; Jirström K
    Front Oncol; 2019; 9():136. PubMed ID: 30931254
    [No Abstract]   [Full Text] [Related]  

  • 25. Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer.
    Fang W; Chen Y; Sheng J; Zhou T; Zhang Y; Zhan J; Liu L; Huang J; Peng P; Zhang L
    J Cancer; 2017; 8(9):1579-1585. PubMed ID: 28775777
    [No Abstract]   [Full Text] [Related]  

  • 26. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer.
    Sun Y; Yu W; Guan W; Cai L; Qiao M; Zheng L; Jiang R; Wang R; Wang L
    Cancer Manag Res; 2019; 11():6397-6410. PubMed ID: 31372044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clear cell carcinoma of the uterine cervix; an unusual HPV-independent tumor: Clinicopathological features, PD-L1 expression, and mismatch repair protein deficiency status of 16 cases.
    Bulutay P; Eren ÖC; Özen Ö; Haberal AN; Kapucuoğlu N
    Turk J Obstet Gynecol; 2023 Sep; 20(3):164-173. PubMed ID: 37667475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of DNA mismatch repair proteins in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
    Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
    Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
    Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
    Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Hasegawa S; Kobayashi N; Okubo N; Tokuhisa M; Goto A; Kurita Y; Sato T; Hosono K; Endo I; Nakajima A; Ichikawa Y
    Intern Med; 2021 Apr; 60(7):977-983. PubMed ID: 33162477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
    Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
    J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
    Kim ST; Klempner SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Lee J
    Oncotarget; 2017 Sep; 8(44):77415-77423. PubMed ID: 29100397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.